One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
本发明的方面之一提供了用于治疗帕
金森病的新型高渗透组合物(H
PC)或高渗透前药(HPP)。H
PCs/HPPs能够穿过
生物屏障后转化为母药活性药物或药物代谢物,因此能够对母药或代谢物能够治疗的疾病进行治疗。此外,HPPs能够到达母药可能无法进入的区域或在目标区域达到足够的浓度,从而实现新的治疗方法。H
PCs/HPPs可以通过各种给药途径给药给受试者,例如,局部施用于具有高浓度的疾病作用部位,或者系统性地给药给
生物受试者,并以更快的速率进入全身循环。